MOTS-c Peptide: Canadian Research Guide (2026)
For laboratory research use only. Nothing on this page is medical advice, and no compound discussed here is offered for human use. MOTS-c is not an approved drug in Canada or elsewhere.
What is MOTS-c?
MOTS-c (mitochondrial open-reading-frame of the twelve-S rRNA type-c) is a 16-amino-acid peptide first characterised by Lee and colleagues in Cell Metabolism in 2015. What set it apart from the thousands of peptides described before it is where it comes from: MOTS-c is encoded within the mitochondrial genome rather than the nuclear genome, making it one of a small family of mitochondrial-derived peptides (MDPs) alongside humanin and the SHLP series. A cell’s mitochondria turning out their own signalling peptide — rather than merely receiving instructions from the nucleus — is the observation that pulled MOTS-c into the centre of metabolic-research conversations, and it has remained one of the most-cited compounds in that literature since.
In Canada, MOTS-c exists only as a research chemical. It has never been authorised as a drug here or in any other jurisdiction, and the material sold on this site is supplied strictly as a laboratory reference compound. This guide covers what the research literature actually says, where its limits are, how the regulatory picture looks in Canada, and what to check before sourcing research-grade material. The concise scientific reference lives on our MOTS-c library page; this guide is the fuller Canadian picture.
Class and mechanism
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate, or safe for a person.
MOTS-c is classified as a mitochondrial-derived peptide. The mechanism discussed most often in the published work is activation of the AMPK pathway — the cell’s central energy sensor — alongside an interaction with the folate–methionine cycle. In cell and animal models, this signalling has been associated with how cells manage glucose uptake and respond to metabolic demand. Under metabolic stress, MOTS-c has also been reported to translocate to the nucleus and influence nuclear gene expression — a mitochondria-to-nucleus signalling direction (“retrograde signalling”) that is itself a subject of active research.
Because of the AMPK connection, MOTS-c is sometimes described informally as an “exercise-mimetic.” That label is research shorthand for a family of preclinical observations, not a demonstrated clinical effect, and it is worth being precise about the difference: the studies describe signalling pathways engaged in laboratory models, not outcomes in people.
Research themes in the literature
Published preclinical work has explored MOTS-c in three broad contexts. First, insulin sensitivity and glucose handling — the original 2015 paper and much of the follow-on rodent work examined how MOTS-c signalling relates to glucose metabolism, particularly under high-fat-diet conditions. Second, exercise capacity and skeletal-muscle metabolism — including work measuring endogenous MOTS-c levels around exercise in humans and administration studies in animal models. Third, metabolic changes associated with aging — the mitochondrial origin of the peptide makes it a natural subject for research on age-related metabolic decline, and reviews (for example Zheng et al., 2023) collect this thread.
Nearly all of this evidence comes from cell and rodent models. Human data is limited to small observational and physiological studies; the peptide’s pharmacokinetics in humans are not well characterised, and no large controlled human trial has been completed.
Evidence — and the gaps that matter
Reading this literature honestly means holding both halves of it. The signal: a mitochondrially encoded peptide that engages a central energy-sensing pathway is a genuinely interesting research object, the foundational paper is well-cited, and the preclinical results have been replicated across multiple laboratories. The gaps: there are no large, controlled human trials; there is no established human dose and no characterised human pharmacokinetic profile; and long-term safety data does not exist. The distance between “interesting in animal models” and “safe and effective in people” has not been closed for MOTS-c, and any source that implies otherwise is ahead of the evidence.
That gap is precisely why the compound remains a research chemical. Laboratories studying it are contributing to an open question, not applying a settled answer.
Regulatory status in Canada
MOTS-c is not authorised by Health Canada for any use. A search of Health Canada’s Drug Product Database returns no authorised product containing it (verified September 2026), it holds no DIN, and no prescription version exists in Canada or any other country. It may be sold in Canada only as a research-use-only laboratory material — not as a drug, a supplement, or a natural health product. Our guide to peptide legality in Canada covers the wider framework.
Purity and the COA question
Because MOTS-c is sold as a research material rather than a regulated pharmaceutical, the meaningful quality question is what is actually in the vial. The answer should never rest on a brand claim. Quantum publishes a per-batch Certificate of Analysis with HPLC purity (target ≥99%) and mass-spectrometry identity confirmation from an independent Canadian laboratory; the batch number is printed on the vial, the MOTS-c COA is downloadable, and the certificate can be verified at the testing lab’s own site. Our certificate of analysis hub explains how to read one. For any research use, purity verification via COA matters more than anything a supplier says about itself.
Where to buy MOTS-c in Canada
Quantum Peptides supplies MOTS-c as 20mg and 40mg lyophilized vials, batch-coded and third-party tested, shipping domestically from Edmonton — see the MOTS-c product page for current stock and the downloadable batch COA. The supplied format is a dry lyophilized powder that a laboratory reconstitutes for its own protocols; we do not sell pre-mixed solutions. For research use only — not for human consumption. New to sourcing research peptides? Start with how to buy research peptides in Canada and how to verify a legit supplier.
MOTS-c next to its research neighbours
MOTS-c is usually discussed alongside two other compounds in the mitochondrial-and-longevity research cluster, and the distinctions matter for research design. SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane — a structural intervention — where MOTS-c is a signalling molecule; the two are not substitutes, and our comparison SS-31 vs MOTS-c covers the contrast in depth. NAD+ is a coenzyme consumed directly in energy metabolism, which makes comparing it to MOTS-c closer to comparing a fuel with a thermostat than comparing two versions of the same thing. Library references: SS-31, NAD+, Epitalon.
Frequently asked questions
Can you buy MOTS-c in Canada?
Yes — as a research-use-only laboratory material from a supplier that publishes per-batch certificates of analysis. It is not an approved drug, and it is not sold for human consumption. Quantum supplies 20mg and 40mg lyophilized research vials.
Does MOTS-c require a prescription in Canada?
There is no prescription to require: no authorised MOTS-c drug product exists in Canada or anywhere else — Health Canada’s Drug Product Database returns no match (verified September 2026). It is available only as a research chemical for laboratory use.
Why is MOTS-c called an “exercise-mimetic”?
The label is research shorthand for preclinical findings that MOTS-c engages the AMPK energy-sensing pathway that exercise also activates in laboratory models. It is a description of a signalling overlap observed in studies, not a demonstrated effect in people.
How is MOTS-c different from NAD+ and SS-31?
They sit at different points in the same system: NAD+ is a coenzyme consumed in energy metabolism, SS-31 is studied for stabilising the inner mitochondrial membrane, and MOTS-c is a signalling peptide studied for how metabolic pathways are regulated. They are research neighbours, not interchangeable compounds.
What formats does research MOTS-c come in?
Quantum supplies lyophilized 20mg and 40mg vials with a batch-specific COA; a laboratory reconstitutes the dry peptide for its own protocols. We do not sell pre-mixed solutions.
How do I verify MOTS-c purity?
Look for a current, batch-specific Certificate of Analysis with HPLC purity (≥99%) and mass-spec identity confirmation from an independent laboratory, with the batch number printed on the vial. Quantum’s COAs can be verified at the testing lab’s own site.
For laboratory research use only. Not for human consumption. Not evaluated for approval by Health Canada. The information on this page summarises published research for educational purposes and is not medical advice.